Latest News
Clear Scientific reports positive CS-1103 Phase 2 Results in removing fentanyl from the Body
2 October 2026 - Clear Scientific, Inc., a US-based biopharmaceutical company, on Thursday announced positive top-line results from its Phase 2 trial of CS-1103, a small-molecule sequestrant that is claimed to immediately bind and inactivate fentanyl...
Avimer Bio and CNIO publish JACS study on computational design of self‑assembling protein cages
2 October 2026 - Avimer Bio, a California-based biotechnology company, in collaboration with structural biologists at the Spanish National Cancer Research Centre (CNIO), announced on Thursday a new publication in the Journal of the American Chemical ...
PearlMatrix P-15 Peptide Enhanced Bone Graft receives Medicare New Technology Add-on Payment (NTAP) status
2 October 2026 - Cerapedics Inc., a US-based, commercial-stage musculoskeletal company involved in bone repair, announced on Thursday that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status ...
Abogen enters Novartis licensing and option agreement to advance RNA programs
2 October 2026 - Abogen Biosciences, a China-based clinical-stage biotechnology group, announced on Friday that it has entered into a licensing and option agreement with Swiss pharmaceutical company Novartis to advance RNA-encoded therapeutics.The ag...
MHRA approves Zepzelca and atezolizumab as first-line maintenance therapy for ES-SCLC in the UK
1 October 2026 - Swedish pharmaceutical company Immedica Pharma AB, backed by investment firms KKR & Co. Inc. (NYSE: KKR) and Impilo, announced on Thursday that its partner, Spanish biopharmaceutical company PharmaMar, has secured MHRA approval f...